- https://doi.org/10.1136/dtb.2025.000009
Mavacamten (▼Camzyos) for obstructive hypertrophic cardiomyopathy.
Abstract
Translate Article 
Take Notes
Translate Article Take Notes Mavacamten (▼Camzyos) for obstructive hypertrophic cardiomyopathy.
ReferencesShowing 10 of 14 papersEfficacy and safety of mavacamten for the treatment of hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of randomized controlled trials 2023 ESC Guidelines for the management of cardiomyopathies. Hypertrophic obstructive cardiomyopathy Hypertrophic cardiomyopathy: a practical approach to guideline directed management Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy VENTRICULAR TACHYCARDIA IN A YOUNG ATHLETE: A LATE MANIFESTATION OF KAWASAKI DISEASE? The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
2 - 10.1097/ms9.0000000000002466
- Oct 1, 2024
- Annals of Medicine & Surgery
- 1238
- 10.1093/eurheartj/ehad194
- Aug 25, 2023
- European heart journal
- 240
- 10.1016/s0140-6736(16)31321-6
- Nov 30, 2016
- The Lancet
- 60
- 10.1016/s0140-6736(21)01205-8
- Sep 30, 2021
- The Lancet
- 132
- 10.1016/j.jacc.2021.09.1381
- Dec 1, 2021
- Journal of the American College of Cardiology
- 245
- 10.1016/j.jacc.2022.04.048
- Jul 1, 2022
- Journal of the American College of Cardiology
- 8
- 10.1016/s0735-1097(20)33276-9
- Mar 1, 2020
- Journal of the American College of Cardiology
- 13
- 10.1093/eurheartj/ehad429
- Jul 24, 2023
- European Heart Journal
- 1597
- 10.1016/s0735-1097(00)00531-3
- Mar 27, 2000
- Journal of the American College of Cardiology
- 51
- 10.1001/jamacardio.2023.3030
- Aug 28, 2023
- JAMA Cardiology
More from: Drug and therapeutics bulletinRecent updates from BNF (BNF 90). Oral contraception and GLP-1 agonists. Nifedipine or labetalol for hypertension in pregnancy. Medicines, but at what cost? Orphan drugs-striking the right balance. Prescribing mistakes in primary care: individual or system error? Prescription charge acceptability. Mavacamten (▼Camzyos) for obstructive hypertrophic cardiomyopathy. Intervention to reduce sedative use. (I)mproving antibiotic susceptibility reports.
- Research Article
- 10.1136/dtb.2025.000046
- Oct 27, 2025
- Drug and therapeutics bulletin
- Research Article
- 10.1136/dtb.2025.000049
- Oct 23, 2025
- Drug and therapeutics bulletin
- Research Article
- 10.1136/dtb.2025.000020
- Oct 21, 2025
- Drug and therapeutics bulletin
- Front Matter
- 10.1136/dtb.2025.000050
- Oct 12, 2025
- Drug and therapeutics bulletin
- Front Matter
- 10.1136/dtb.2025.000005
- Sep 29, 2025
- Drug and therapeutics bulletin
- Research Article
- 10.1136/dtb.2024.000066
- Sep 23, 2025
- Drug and therapeutics bulletin
- Research Article
- 10.1136/dtb.2025.000036
- Sep 22, 2025
- Drug and therapeutics bulletin
- Research Article
- 10.1136/dtb.2025.000009
- Sep 19, 2025
- Drug and therapeutics bulletin
- Research Article
- 10.1136/dtb.2025.000045
- Sep 19, 2025
- Drug and therapeutics bulletin
- Front Matter
- 10.1136/dtb.2025.000025
- Sep 4, 2025
- Drug and therapeutics bulletin
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
What is the difference between bacteria and viruses?
What is the function of the immune system?Can diabetes be passed down from one generation to the next?